Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 16/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427673 | 0.84 | MRGPRX4 (0.70) | MRGPRX4 | |
| SCHEMBL10877691 | 0.82 | CYP1A2 (0.54) | MRGPRX4FFAR1 | |
| SCHEMBL30278570 | 0.79 | MRGPRX4 (0.69) | MRGPRX4FFAR1 | |
| SCHEMBL3791436 | 0.79 | MRGPRX4 (0.69) | MRGPRX4FFAR1 | |
| SCHEMBL8015966 | 0.77 | MRGPRX4 (0.54) | MRGPRX4FFAR1 | |
| SCHEMBL10875248 | 0.77 | MEN1 (0.56) | MRGPRX4 | |
| SCHEMBL10499547 | 0.76 | FFAR1 (0.56) | MRGPRX4FFAR1 | |
| SCHEMBL10673556 | 0.76 | MRGPRX4 (0.67) | MRGPRX4FFAR1 | |
| SCHEMBL680193 | 0.76 | MRGPRX4 (0.61) | MRGPRX4 | |
| SCHEMBL10661457 | 0.76 | MRGPRX4 (0.61) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999053930-A1 | SYNTHETIC GLYCOAMINES AND METHODS FOR THEIR USE, ALONE OR IN COMBINATION WITH OTHER THERAPIES, THAT AFFECT CELL ADHESION, INHIBIT CANCER CELL GROWTH AND METASTASIS, AND INDUCE APOPTOSIS | GLINSKII GUENNADI V (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |